GPC3 and hepatocellular carcinoma: A noteworthy investigation centered on CAR-T cells targeting glypican-3 (GPC3), a unique antigen commonly found in advanced HCC cases, revealed impressive antitumor effectiveness, with several patients showing marked tumor reduction and increased survival duration (100).